Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2214/AJR.10.5147 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activatable Porphyrin-Based Sensors, Photosensitizers and Combination Therapeutics.
JACS Au
January 2025
Department of Chemistry, Cancer Center at Illinois and Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, 61801 Illinois United States.
Porphyrins, known as the "pigments of life", have evolved from their natural roles into versatile tools for biomedical applications. The development of activatable porphyrins has significantly expanded their utility, enabling precise responses to a carefully selected target analyte. These advances have broadened their use in imaging, diagnosis, and therapy.
View Article and Find Full Text PDFDiagnosis and Management of Progressive Corticobasal Syndrome.
Curr Treat Options Neurol
July 2024
Department of Neurology, Division of Behavioral Neurology, Stanford Neuroscience Health Center, 453 Quarry Road, Palo Alto, CA 94304, USA.
Purpose Of Review: The purpose of this review is to discuss the clinical, radiological, and neuropathological heterogeneity of corticobasal syndrome (CBS), which can complicate the determination of underlying etiology and lead to inaccurate treatment decisions. Though the most common diagnosis is corticobasal degeneration (CBD), the spectrum of underlying pathologies expands beyond CBD and can overlap with other neurodegenerative diseases and even the neuroimmunology field. We will review possible clinical presentations and cues that can point towards the etiology.
View Article and Find Full Text PDFAutomated Quantitative Assessment of Retinal Vascular Tortuosity in Patients with Sickle Cell Disease.
Ophthalmol Sci
November 2024
Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California, San Diego, La Jolla, California.
Objective: To quantitatively assess the retinal vascular tortuosity of patients with sickle cell disease (SCD) and retinopathy (SCR) using an automated deep learning (DL)-based pipeline.
Design: Cross-sectional study.
Subjects: Patients diagnosed with SCD and screened for SCR at an academic eye center between January 2015 and November 2022 were identified using electronic health records.
Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis.
Gastroenterol Hepatol (N Y)
November 2024
Houston Methodist Hospital, Houston Liver Institute, Houston, Texas.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease, is a major global health issue and a leading cause of chronic liver disease. The prevalence of MASLD is increasing globally, with the disease in some patients progressing to metabolic dysfunction-associated steatohepatitis (MASH), which significantly raises the risk of fibrosis, cirrhosis, and adverse outcomes. Accurate identification of patients with at-risk MASH, defined as MASH with a fibrosis stage of 2 or higher, is critical for timely intervention and management.
View Article and Find Full Text PDFSerum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.
Alzheimers Dement (Amst)
January 2025
Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC Amsterdam The Netherlands.
Introduction: Blood-based glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) have shown promising prognostic potential in Alzheimer's disease (AD), but their applicability in clinical settings where comorbidities are prevalent remains uncertain.
Methods: Simoa assays quantified GFAP, NfL, and pTau181 in retrospectively retrieved prediagnostic serum samples from 102 AD patients and 21 non-AD controls.
Results: Higher serum GFAP levels predicted earlier clinical presentation and faster subsequent Mini-Mental State Examination decline in AD patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!